• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Human papillomavirus vaccination at the first opportunity: An overview
Hum Vaccin Immunother. 2023 May 23:2213603. doi: 10.1080/21645515.2023.2213603. Online ahead of print.ABSTRACTThe Advisory Committee on Immunization Practices (ACIP) has recommended human papillomavirus (HPV) vaccination for adolescents in the United States since 2006. Though recommended at a similar time to the routine recommendations for adolescent tetanus, diphtheria, and acellular pertussis vaccination (Tdap) and quadrivalent meningococcal vaccination (MCV4), HPV vaccine uptake has consistently lagged behind these other adolescent vaccines. The ACIP recommends HPV vaccination at 11-12 y, with vaccination starting at 9 ...
Source: Cancer Control - May 23, 2023 Category: Cancer & Oncology Authors: Robert A Bednarczyk Noel T Brewer Melissa B Gilkey Sherri Zorn Rebecca B Perkins Kristin Oliver Debbie Saslow Source Type: research

Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
Hum Vaccin Immunother. 2023 Dec 31;19(1):2204784. doi: 10.1080/21645515.2023.2204784.ABSTRACTHuman papillomavirus (HPV) vaccination uptake in the United States remains suboptimal, and continues to trail that of tetanus, diphtheria, and acellular pertussis (Tdap) vaccination and quadrivalent meningococcal conjugate vaccination (MCV4). This is despite these three vaccines all being recommended for routine adolescent use within the 2005-2006 time period. One strategy to improve HPV vaccination is starting the vaccine series at the first opportunity - currently as young as 9 years of age. Little is known about the epidemiology...
Source: Cancer Control - May 4, 2023 Category: Cancer & Oncology Authors: Robert A Bednarczyk Heather M Brandt Source Type: research

Effect of medical staff training on vaccination coverage in outpatients with cancer: An interventional multicenter before-and-after study
CONCLUSION: As expected, VC was very low in patients with cancer, consistent with the literature. There was no impact of the intervention for pneumococcal and influenza VC.PMID:36654840 | PMC:PMC9841025 | DOI:10.1016/j.jvacx.2023.100261
Source: Cancer Control - January 19, 2023 Category: Cancer & Oncology Authors: Pierre Rivi ère Nicolas Penel Karine Faure Guillaume Marie Abeer Najem Marie-Karelle Rivi ère Sophie Panaget Source Type: research

The COVID-19 pandemic and disruptions to essential health services in Kenya: a retrospective time-series analysis
Lancet Glob Health. 2022 Sep;10(9):e1257-e1267. doi: 10.1016/S2214-109X(22)00285-6.ABSTRACTBACKGROUND: Public health emergencies can disrupt the provision of and access to essential health-care services, exacerbating health crises. We aimed to assess the effect of the COVID-19 pandemic on essential health-care services in Kenya.METHODS: Using county-level data routinely collected from the health information system from health facilities across the country, we used a robust mixed-effect model to examine changes in 17 indicators of essential health services across four periods: the pre-pandemic period (from January, 2018 to ...
Source: Cancer Control - August 12, 2022 Category: Cancer & Oncology Authors: Helen Kiarie Marleen Temmerman Mutono Nyamai Nzisa Liku Wangari Thuo Violet Oramisi Lilly Nyaga Janette Karimi Phidelis Wamalwa Gladwell Gatheca Valerian Mwenda Loice Achieng Ombajo S M Thumbi Essential Health Services Data Monitoring and Evaluation sub-w Source Type: research

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial
CONCLUSION: The BR-TD-1001 satisfied the immunological non-inferiority criterion against diphtheria and tetanus, with a clinically acceptable safety profile.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04618939.PMID:34931494 | DOI:10.3346/jkms.2021.36.e313
Source: Cancer Control - December 21, 2021 Category: Cancer & Oncology Authors: Ui Yoon Choi Ki Hwan Kim Jin Lee Byung Wook Eun Hwang Min Kim Kyung-Yil Lee Dong Ho Kim Sang Hyuk Ma Jina Lee Jong-Hyun Kim Source Type: research

Association of Maternal Cervical Disease With Human Papillomavirus Vaccination Among Offspring
CONCLUSIONS AND RELEVANCE: In this analysis of salience bias in childhood vaccination decisions, mothers' personal history of cervical cancer or cervical biopsy was not associated with greater vaccination rates among children against HPV. These findings suggest that salience of vaccine-preventable outcomes may not have a major impact on childhood vaccine hesitancy in HPV; the role of salience should be investigated for other vaccines.PMID:34902041 | DOI:10.1001/jamanetworkopen.2021.34566
Source: Cancer Control - December 13, 2021 Category: Cancer & Oncology Authors: Christopher M Worsham Jaemin Woo Andr é Zimerman Charles F Bray Anupam B Jena Source Type: research